Background: Hepatocellular carcinoma (HCC) is the most common primary hepatic tumor and one of the most common cancers worldwide. HCC is a primary malignancy of hepatocellular origin. Objectives:The aim of study is to combinate therapy of transarterial chemoembolization and percutaneousethanol injection afterward emerging metatasis caused by fine needle aspiration cytology. Subjects and method: A 50 years old male patient with hepatocellular carcinoma having a diameter of tumor more than 5 cm was treated by combination of transarterial chemoembolization and percutaneous ethanol injection from December 2000. Results & Conclusion: Results of study showed that: Transarterial chemoembolization and percutaneous ethanol injection are the two of non-surgical methods for treatment of hepatocellular carcinoma which are most commonly available in applied clinical activities at present. Up to now, the patient's life expectancy after therapy is more than 6 years that means the result of treatment is very good. However, the emerging metatasis into the anterior-right-Iower chest wall that was caused by fine needle aspiration cytology should be reviewed for further evaluating clinical experience, especially in cases with quite clear imaging features of untrasonography and significantly elevated AFP level higher than 200 ng/rnl.
Carcinoma ; Hepatocellular/ pathology ; therapy

With the development of modern liver surgical techniques and the progress of perioperative management,the survival rate after resection of hepatocellular carcinoma has been greatly improved,but the high recurrence and metastasis rate still limits the long-term survival after surgery. Preoperative neoadjuvant therapy has been confirmed to significantly reduce the postoperative recurrence rate and prolong survival in other types of cancer,but there has been a lack of effective systemic therapy for hepatocellular carcinoma for a long time,so the efficacy and regimen of neoadjuvant therapy for hepatocellular carcinoma are still controversial. PD-1/PD-L1 monoclonal antibody combined with anti-angiogenic targeted drugs has become a first-line regimen in systemic therapy for advanced hepatocellular carcinoma. This regimen has definite efficacy and high safety,bringing hope for neoadjuvant therapy of hepatocellular carcinoma. Recently,three clinical trials of neoadjuvant immunotherapy for hepatocellular carcinoma have been published internationally,which preliminarily suggest the efficacy and safety of neoadjuvant immunotherapy for hepatocellular carcinoma and lay a solid foundation for carrying out larger sample clinical studies in the future.
Humans ; Carcinoma, Hepatocellular/pathology* ; Neoadjuvant Therapy ; Liver Neoplasms/pathology* ; Immunotherapy

Chronic inflammatory responses have long been observed to be associated with various types of cancer and play decisive roles at different stages of cancer development. Inflammasomes, which are potent inducers of interleukin (IL)-1β and IL-18 during inflammation, are large protein complexes typically consisting of a Nod-like receptor (NLR), the adapter protein ASC, and Caspase-1. During malignant transformation or cancer therapy, the inflammasomes are postulated to become activated in response to danger signals arising from the tumors or from therapy-induced damage to the tumor or healthy tissue. The activation of inflammasomes plays diverse and sometimes contrasting roles in cancer promotion and therapy depending on the specific context. Here we summarize the role of different inflammasome complexes in cancer progression and therapy. Inflammasome components and pathways may provide novel targets to treat certain types of cancer; however, using such agents should be cautiously evaluated due to the complex roles that inflammasomes and pro-inflammatory cytokines play in immunity.
Animals ; Carcinoma ; immunology ; pathology ; therapy ; Gastrointestinal Neoplasms ; immunology ; pathology ; therapy ; Humans ; Inflammasomes ; metabolism ; Melanoma ; immunology ; pathology ; therapy ; Neoplasms ; immunology ; pathology ; therapy ; Skin Neoplasms ; immunology ; pathology ; therapy

Carcinoma, Hepatocellular ; diagnosis ; pathology ; therapy ; Humans ; Liver Neoplasms ; diagnosis ; pathology ; therapy

Carcinoma, Squamous Cell ; pathology ; therapy ; Female ; Humans ; Neoplasm Invasiveness ; Uterine Cervical Neoplasms ; pathology ; therapy

Adult ; Carcinoma, Squamous Cell ; pathology ; therapy ; Female ; Humans ; Submandibular Gland Neoplasms ; pathology ; therapy

Carcinoma, Papillary ; diagnosis ; pathology ; therapy ; Humans ; Practice Guidelines as Topic ; Thyroid Neoplasms ; diagnosis ; pathology ; therapy

Carcinoma, Hepatocellular ; pathology ; therapy ; Humans ; Liver Neoplasms ; pathology ; therapy ; Neoplasm Metastasis ; Neoplasm Recurrence, Local

Adolescent ; Adult ; Carcinoma, Small Cell ; pathology ; therapy ; Female ; Humans ; Ovarian Neoplasms ; pathology ; therapy

Aged ; Carcinoma, Non-Small-Cell Lung ; pathology ; therapy ; Humans ; Lung Neoplasms ; pathology ; therapy